Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 3512345...102030...Last »

U.S. healthcare spending to climb 5.3 percent in 2018: agency

United States health spending is projected to rise 5.3 percent in 2018, reflecting rising prices of medical goods and services and higher Medicaid costs.

Read More »

Xtandi delays prostate cancer spread in early-stage disease

Use of Xtandi in early-stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone.

Read More »

Novartis says Entresto could become $5 billion a year blockbuster drug

A Novartis executive said the Swiss company’s heart failure medicine Entresto could be used more widely in the future.

Read More »

German watchdog calls for direct comparison of cancer immunotherapies

Germany’s drug assessment body criticized a lack of data directly comparing drugs in a promising new class of cancer immunotherapy, saying physicians could be overwhelmed or misled by the available information.

Read More »

Neurontin prescriptions surge amid opioid crisis

Prescriptions for nerve pain medicines like Neurontin and Lyrica more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests.

Read More »

Drugmakers raise 2018 U.S. prices

2018 opened with elevated U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit.

Read More »

New drug approvals hit 21-year high in 2017

U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light — more than double the previous year — while the figure also rose in the EU.

Read More »

China: U.S. should do more to cut opioid demand

The United States should take action to reduce demand for the drugs fueling its deadly opioid crisis, a top Chinese drug control official said.

Read More »

Teva Announces Exclusive U.S. Launch of Generic Version of Reyataz

Teva Pharmaceutical Industries Ltd. announced the exclusive launch of a generic version of Reyataz (atazanavir) capsules in the U.S.

Read More »

Kyprolis improves overall survival in blood cancer

Amgen Inc. said a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Read More »

PhRMA sues to stop California drug price law

The trade group representing U.S. drugmakers filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices.

Read More »

U.S. healthcare spending growth slowed in 2016

Growth in healthcare spending in the United States slowed in 2016 following two years of expansion under the Affordable Care Act.

Read More »

Exclusive: U.S. health regulator Verma eyes new methods for drug pricing

The U.S. government is considering setting new payment methods aimed at curbing costs for Medicare and Medicaid coverage of breakthrough medical treatments with very high prices, particularly novel gene-based therapies for cancer and other diseases, a top health official said.

Read More »

Azar says drug pricing a top priority

Alex Azar – a former drug industry exec who Republicans nominated to run the Department of Health and Human Services – promised to lower drug prices that he said are too high, saying he would look at abuse of patent laws that delays generic competition.

Read More »

Opioid crisis cost U.S. $504 billion in 2015

Opioid drug abuse cost the U.S. economy as much as $504 billion in 2015, White House economists said in a report.

Read More »

PeptiDream Bags R&D Pact With Bayer

Peptidream Inc. scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment of multiple disease targets.

Read More »

CryoPort Grabs Contracts for Gilead, Novartis CAR-T Products

In the world of developing and manufacturing cell-based therapeutics an approved medication for any indication is only part of the business plan. The other aspect is delivering the product to patients. That’s where logistics companies like CryoPort Inc. come into play.

Read More »

U.S. committee recommends GSK shingles vaccine over Merck rival

The committee responsible for U.S. vaccination schedules gave a preferential recommendation to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck’s established product Zostavax.

Read More »

2017 Annual Report: Top 50 Companies – The Corner Turned

For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.

Read More »

Roche bladder cancer drug struggles

Tecentriq has lost market share to Merck & Co.’s rival Keytruda since a study showed Roche’s immunotherapy drug failed to improve overall survival in bladder cancer.

Read More »

Page 2 of 3512345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation